Further optimisation of a macromolecular ocular irritation test (OptiSafe


Journal

Cutaneous and ocular toxicology
ISSN: 1556-9535
Titre abrégé: Cutan Ocul Toxicol
Pays: England
ID NLM: 101266892

Informations de publication

Date de publication:
Mar 2023
Historique:
pmc-release: 01 03 2024
pubmed: 21 1 2023
medline: 10 3 2023
entrez: 20 1 2023
Statut: ppublish

Résumé

OptiSafe The OS test measures chemically induced damage to macromolecules and relates these measured values to ocular irritancy. To improve the performance of OS, we made updates to the material to be tested physiochemical handling procedures, prediction model, and test method to include tear-level concentrations of ascorbic acid. We then retested the 78 chemicals from the prior OS-coded validation study in triplicate and compared the accuracy of the 'nonirritant versus irritant' prediction for the further optimized method with the prior results. We report that for the detection of 'nonirritant' versus 'irritant' (GHS NC versus categories 2B/A and 1) test substances, the further optimized OS test with ascorbic acid compared with the original version has a FP rate that is reduced from 40.0 to 22.2%, the false-negative (FN) rate remains at 0.0%, and the accuracy improved from 80.3% to 89.2%. A comparison to OECD-adopted tests demonstrates that the further optimized OS test, like the original method, has a higher accuracy and lower FN rate for the detection of 'nonirritants' versus 'irritants' (GHS Category NC versus 2B/A and 1) than the other eye irritation tests (BCOP, EpiOcular

Identifiants

pubmed: 36669195
doi: 10.1080/15569527.2023.2170067
pmc: PMC10381028
mid: NIHMS1912074
doi:

Substances chimiques

Irritants 0
Ascorbic Acid PQ6CK8PD0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-48

Subventions

Organisme : NIEHS NIH HHS
ID : R44 ES025501
Pays : United States
Organisme : NIEHS NIH HHS
ID : SB1 ES025501
Pays : United States

Références

Cutan Ocul Toxicol. 2020 Sep;39(3):180-192
pubmed: 32586141
Toxicol In Vitro. 2021 Apr;72:105070
pubmed: 33352259
Ocul Surf. 2009 Oct;7(4):176-85
pubmed: 19948101
Toxicol In Vitro. 2019 Jun;57:154-163
pubmed: 30817952
Toxicol In Vitro. 2019 Sep;59:100-114
pubmed: 30981694
Toxicol In Vitro. 2021 Oct;76:105208
pubmed: 34216722
Toxicol In Vitro. 2019 Dec;61:104628
pubmed: 31419508
Toxicol In Vitro. 2022 Apr;80:105313
pubmed: 35033652

Auteurs

Stewart Lebrun (S)

Lebrun Labs LLC, Anaheim, CA, USA.

Sara Chavez (S)

Lebrun Labs LLC, Anaheim, CA, USA.

Linda Nguyen (L)

Lebrun Labs LLC, Anaheim, CA, USA.

Roxanne Chan (R)

Lebrun Labs LLC, Anaheim, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH